Group 1 - The core viewpoint of the report emphasizes the importance of reviewing the full semi-annual report for a comprehensive understanding of the company's operational results, financial status, and future development plans [1] - The board of directors, supervisory board, and senior management guarantee the authenticity, accuracy, and completeness of the semi-annual report, taking legal responsibility for any false statements or omissions [1] - The report indicates that there are no profit distribution plans or capital reserve conversion plans approved by the board during the reporting period [2] Group 2 - The company has reported significant changes in the operating conditions during the reporting period, with a focus on matters that have had or are expected to have a major impact on the company's operations [2] - The controlling shareholder and its concerted actors have a high proportion of pledged and judicially frozen shares, with 77.15% of their shares being judicially frozen and 60.22% pledged as of June 30, 2025 [3] - The risk of judicial disposal of shares held by the controlling shareholder and its concerted actors is high due to multiple lawsuits and significant amounts involved, which could potentially lead to a change in actual control of the company [3]

Group 1 - The core point of the news highlights significant changes in the shareholding structure of the company's controlling shareholder and associated parties, indicating a high risk of judicial disposal of shares [1][2] - As of June 30, 2025, the controlling shareholder and its concerted parties held 10.72% of the company's shares, with 77.15% of these shares being judicially frozen and 60.22% pledged [2] - The judicial auction of 1.637995 million shares by the controlling shareholder's concerted party resulted in a 0.31% decrease in their shareholding [2] Group 2 - The company emphasizes the importance of understanding the significant changes in its operational situation and the potential future impacts due to the high proportion of shares being pledged and frozen [1][2] - The ongoing litigation and execution cases involving the controlling shareholder and its concerted parties pose a substantial risk, potentially leading to changes in the actual control of the company [2]

Company Overview - Beihai Guofa Chuanshan Biological Co., Ltd. is primarily engaged in pharmaceutical manufacturing and distribution, judicial IVD (in vitro diagnostics), and molecular medical imaging centers [3][11] - The company operates under various business models including direct sales, agency sales, and self-owned sales teams [5][6] Financial Performance - For the first half of 2025, the company reported a revenue of approximately 153.73 million yuan, a decrease of 13.02% compared to the same period last year [2] - The total profit for the period was a loss of approximately 4.58 million yuan, improving from a loss of 13.69 million yuan in the previous year [2] - The net profit attributable to shareholders was approximately -5.84 million yuan, compared to -16.11 million yuan in the same period last year [2] Industry Context - The pharmaceutical manufacturing industry in China saw a revenue of 1,227.52 billion yuan in the first half of 2025, a decline of 1.2% year-on-year [12] - The drug distribution industry experienced a significant slowdown, with a growth rate of only 0.6% in 2024, the lowest in 15 years [12] - The IVD market is expected to remain stable, with a projected market size of less than 120 billion yuan in 2024, indicating limited growth potential [13] Business Segments - The pharmaceutical manufacturing segment includes products such as eye drops, granules, and traditional Chinese medicine, with a focus on quality control and compliance with GMP standards [3][11] - The judicial IVD segment, operated by the subsidiary Gaoshen Biological, focuses on DNA testing equipment and services, utilizing a direct sales model primarily targeting public security units [5][6] - The molecular medical imaging center, managed by Beijing Xiangya, collaborates with medical institutions to provide imaging services and sells medical devices [11] Market Trends - The pharmaceutical industry is characterized by cyclical, regional, and seasonal demand patterns, with a relatively stable long-term outlook despite short-term fluctuations [11] - The IVD industry is witnessing a shift towards automation and intelligent detection technologies, driven by advancements in AI and big data [13][14]

目前，控股股东及一致行动人涉及的诉讼或执行案件较多、涉案金额较大，其持有的公司股 份被司法处置的风险较高。如果被司法处置的股份占比较大，可能会导致公司实际控制权发生变 更。 | 姚芳媛 | | 境内自然人 | 2.35 | 12,323,000 | | | 0 | 质押 | | 12,323,000 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 郭焕珍 | | 境内自然人 2.29 | | 12,026,617 | | | 0 | 无 | | | | 北海市路港建设投资开 | | | | | | | | | | | | 国有法人 | | 2.29 12,017,364 | | | | 0 | 无 | | | | | 发有限公司 | | | | | | | | | | | | 温州启元资产管理有限 | | | | | | | | | | | | 公司－启元尊享 1 | | 号私募 其他 1.91 | | 10,000,000 | | | | 0 | 无 | | | 证券投资基金 | | | | | | | | | ...

Group 1 - The core point of the article is that Guofang Co., Ltd. reported a decline in revenue and a net loss for the first half of 2025, indicating financial challenges [1] - The company achieved operating revenue of 153,729,775.86 yuan for the first half of 2025, which represents a year-on-year decrease of 13.02% [1] - The net profit attributable to shareholders of the listed company was -5,841,730.40 yuan, indicating a loss during this period [1]

公司代码：600538 公司简称：国发股份 北海国发川山生物股份有限公司 2025 年半年度报告 1 / 147 北海国发川山生物股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 北海国发川山生物股份有限公司2025 年半年度报告 二、 公司全体董事出席董事会会议。 四、 公司负责人姜烨、主管会计工作负责人尹志波及会计机构负责人（会计主管人员）李斌斌 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 三、 本半年度报告未经审计。 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述可能存在的风险，敬请查阅第三节管理层讨论与分析中可能面临 的风险的相 ...

Meeting Overview - The 10th meeting of the 11th Supervisory Board of Beihai Guofa Chuanshan Biological Co., Ltd. was held on July 31, 2025, with all three supervisors participating in the voting [2][5] - The meeting was legally convened and chaired by Mr. Lü Qiujun [2] Audit Institution Appointment - The Supervisory Board approved the proposal to appoint Shanghai Shuhui Accounting Firm (Special General Partnership) as the special audit institution for the company's 2025 A-share issuance to specific targets [3][8] - The appointment does not require submission to the shareholders' meeting for approval [4] Audit Institution Details - Shanghai Shuhui Accounting Firm was established in January 1981 and has undergone several transformations, with its current form established in December 2013 [8] - The firm has provided audit services to 72 listed companies in 2024, with a total audit revenue of 0.81 billion yuan [9] - The firm has a total revenue of 0.683 billion yuan in 2024, with 0.204 billion yuan from securities business [9][10] Voting Results - The proposal received unanimous support from the Supervisory Board, with 3 votes in favor and no opposition or abstentions, representing 100% of the valid voting rights [5] Board Meeting Overview - The 17th meeting of the 11th Board of Directors was also held on July 31, 2025, with all 9 directors participating [21] - The Board approved the proposal to appoint the same audit institution for the 2025 A-share issuance, with a unanimous vote of 9 in favor [32][33] Financing Guarantee - The company agreed to provide a guarantee for its wholly-owned subsidiary, Beihai Guofa Pharmaceutical Co., Ltd., for a loan of 20 million yuan from China Postal Savings Bank [29][34] - The loan term is set for 3 years, and the company will not charge any guarantee fees [34][41] - The total amount of external guarantees before this loan was 0 yuan, and the new guarantee represents 2.58% of the company's audited net assets [44]

证券代码：600538 证券简称：国发股份 公告编号：临 2025-037 北海国发川山生物股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 北海国发医药有限责任公司 | 2,000.00 万元 | | --- | --- | --- | --- | | 担保对 象 | 实际为其提供的担保余额 | | 0 万元 | | | 是否在前期预计额度内 | □是 否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 2,000 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 2.58 | | 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 100 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2025-038 北海国发川山生物股份有限公司 关于聘请公司专项审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：拟聘任的会计师事务所名称：上会会计师事务所（特殊普通 合伙）（以下简称"上会会计师事务所"或"上会所"）。 北海国发川山生物股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日 召开的第十一届董事会第十七次会议、第十一届监事会第十次会议审议通过了 《关于 2025 年度以简易程序向特定对象发行 A 股股票聘请专项审计机构的议案》， 同意聘请上会会计师事务所为公司 2025 年度以简易程序向特定对象发行 A 股股 票的专项审计机构。现将相关情况公告如下： 一、聘任专项审计机构的基本情况 （一）审计机构信息 1、基本信息 上会所原名上海会计师事务所，成立于 1981 年 1 月，系财政部在上海试点 成立的全国第一家会计师事务所。1998 年 12 月按财政部、中国证券监督管理委 员会的要求，改制为上海上会会计师事务所有限 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2025-036 北海国发川山生物股份有限公司 第十一届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北海国发川山生物股份有限公司（以下简称"公司"）第十一届监事会第十次 会议于 2025 年 7 月 31 日在公司二楼会议室以现场及通讯方式召开，会议通知及 会议资料于 2025 年 7 月 25 日以电子邮件方式发出。本次会议应参与表决监事 3 人，实际参与表决监事 3 人。会议由监事会主席吕秋军先生主持，会议的召集、 召开和表决符合《公司法》及《公司章程》的有关规定，会议召开合法有效。 二、监事会会议审议情况 本议案无需提交股东大会审议。 具体内容详见公司 2025 年 8 月 1 日在《中国证券报》《证券时报》《证券日报》 《上海证券报》和上海证券交易所网站（https://www.sse.com.cn）披露的《关 于聘请公司专项审计机构的公告》（临 2025-038）。 1 表决结果：同意【3】票，反对【0】票 ...